Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Dermatology | Family Medicine
Clinical Trials: Malignant Melanoma
A listing of clinical trials currently looking for volunteers to enroll in Malignant Melanoma studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Arizona
Tucson :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
California
Beverly Hills : Call for Information (Investigational Site 0061) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Concord :
A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma
Encinitas :
A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma
La Jolla : Moores UCSD Cancer Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
La Jolla :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
View More »
Los Angeles :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Los Angeles :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Los Angeles :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Orange : Chao Family Comprehensive Cancer Center
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
San Diego : Rady Children's Hospital
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
San Francisco : St Mary's Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
San Francisco :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Colorado
Aurora :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Aurora :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Aurora :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Connecticut
New Haven : Yale University School Of Medicine
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Florida
Miami Beach : Mount Sinai Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Tampa :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tampa :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Illinois
Chicago : Rush University Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Chicago :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Niles : Oncology Specialists, SC
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Park Ridge :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Park Ridge :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Indiana
Goshen :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Indianapolis :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Iowa
Iowa City :
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
Massachusetts
Boston :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Boston : Dana Farber Cancer Institute
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Michigan
Detroit :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Detroit :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Minnesota
Rochester :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Missouri
St Louis :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
St. Louis :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Nevada
Las Vegas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
New Jersey
Morristown : Atlantic Melanoma Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Randolph :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New York
New York :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New York :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
New York : Memorial Sloan Kettering Cancer Center
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New York :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
North Carolina
Charlotte :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Durham : Call for Information (Investigational Site 0036) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Oregon
Portland : Oregon Health and Science University
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pennsylvania
Bethlehem :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Pittsburgh : University of Pittsburgh
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pittsburgh :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Tennessee
Memphis : St. Jude Children's Research Hospital
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Memphis : St. Jude Children's Research Hospital
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Nashville :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Nashville :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Nashville : Call for Information (Investigational Site 0033) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
View More »
Nashville :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Texas
Dallas : Mary Crowley Cancer Research Centers
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Dallas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Dallas : Mary Crowley Cancer Research Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Dallas :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Dallas : Mary Crowley Cancer Research Center
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
View More »
Houston :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Houston : The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Houston : University of Texas MD Anderson Cancer Center
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Utah
Salt Lake City : Huntsman Cancer Institute
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Washington
Seattle :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Albania
Tirana :
A Study of RO5185426 in Patients With Metastatic Melanoma
Australia
Ashford Sa :
A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma
Melbourne :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Melbourne :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Wentworthville :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Belgium
Bruxelles :
A Study of RO5185426 in Patients With Metastatic Melanoma
Wilrijk :
A Study of RO5185426 in Patients With Metastatic Melanoma
Bosnia and Herzegovina
Banja Luka :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sarajevo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Brazil
Rio de Janeiro - Rj :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sao Paulo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Bulgaria
Plovdiv :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sofia :
A Study of RO5185426 in Patients With Metastatic Melanoma
Canada
Edmonton :
A Study of RO5185426 in Patients With Metastatic Melanoma
Halifax :
A Study of RO5185426 in Patients With Metastatic Melanoma
Hamilton :
A Study of RO5185426 in Patients With Metastatic Melanoma
London :
A Study of RO5185426 in Patients With Metastatic Melanoma
Montreal :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Ottawa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Quebec City :
A Study of RO5185426 in Patients With Metastatic Melanoma
Toronto :
A Study of RO5185426 in Patients With Metastatic Melanoma
Toronto :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Vancouver :
A Study of RO5185426 in Patients With Metastatic Melanoma
Winnipeg :
A Study of RO5185426 in Patients With Metastatic Melanoma
Winnipeg :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Colombia
Medellin :
A Study of RO5185426 in Patients With Metastatic Melanoma
Croatia
Zagreb :
A Study of RO5185426 in Patients With Metastatic Melanoma
Czech Republic
Brno :
A Study of RO5185426 in Patients With Metastatic Melanoma
Hradec Kralove :
A Study of RO5185426 in Patients With Metastatic Melanoma
Olomouc :
A Study of RO5185426 in Patients With Metastatic Melanoma
Ostrava :
A Study of RO5185426 in Patients With Metastatic Melanoma
Praha :
A Study of RO5185426 in Patients With Metastatic Melanoma
Ecuador
Guayaquil :
A Study of RO5185426 in Patients With Metastatic Melanoma
Portoviejo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Finland
Helsinki :
A Study of RO5185426 in Patients With Metastatic Melanoma
France
Bordeaux :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Lille :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nice :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Paris :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Germany
Essen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Frankfurt :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Freiburg : University Medical Center Freiburg, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Jena :
A Study of RO5185426 in Patients With Metastatic Melanoma
Kiel :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Köln : University Medical Center Collogne, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Mannheim :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Münster :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tübingen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Wiesbaden :
A Study of RO5185426 in Patients With Metastatic Melanoma
Greece
Athens :
A Study of RO5185426 in Patients With Metastatic Melanoma
Heraklion :
A Study of RO5185426 in Patients With Metastatic Melanoma
India
Hyderabad :
A Study of RO5185426 in Patients With Metastatic Melanoma
Lucknow :
A Study of RO5185426 in Patients With Metastatic Melanoma
Nashik :
A Study of RO5185426 in Patients With Metastatic Melanoma
New Delhi :
A Study of RO5185426 in Patients With Metastatic Melanoma
Trivandrum :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Vellore :
A Study of RO5185426 in Patients With Metastatic Melanoma
Ireland
Cork :
A Study of RO5185426 in Patients With Metastatic Melanoma
Dublin :
A Study of RO5185426 in Patients With Metastatic Melanoma
Galway :
A Study of RO5185426 in Patients With Metastatic Melanoma
Limerick :
A Study of RO5185426 in Patients With Metastatic Melanoma
Waterford :
A Study of RO5185426 in Patients With Metastatic Melanoma
Israel
Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Jerusalem : Oncology institute, Shaare Zedek Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Oncology Institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel-hashomer :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Italy
Bari :
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Brescia :
A Study of RO5185426 in Patients With Metastatic Melanoma
Firenze :
A Study of RO5185426 in Patients With Metastatic Melanoma
Genova :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Meldola :
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano :
A Study of RO5185426 in Patients With Metastatic Melanoma
Napoli :
A Study of RO5185426 in Patients With Metastatic Melanoma
Padova :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pisa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Roma :
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena :
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Udine :
A Study of RO5185426 in Patients With Metastatic Melanoma
Korea, Republic of
Seoul :
A Study of RO5185426 in Patients With Metastatic Melanoma
Lithuania
Klaipeda :
A Study of RO5185426 in Patients With Metastatic Melanoma
Vilnius :
A Study of RO5185426 in Patients With Metastatic Melanoma
Macedonia, The Former Yugoslav Republic of
Skopje :
A Study of RO5185426 in Patients With Metastatic Melanoma
Mexico
Leon :
A Study of RO5185426 in Patients With Metastatic Melanoma
Mexico City :
A Study of RO5185426 in Patients With Metastatic Melanoma
Netherlands
Amsterdam :
A Study of RO5185426 in Patients With Metastatic Melanoma
Amsterdam :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Blaricum :
A Study of RO5185426 in Patients With Metastatic Melanoma
Breda :
A Study of RO5185426 in Patients With Metastatic Melanoma
Groningen :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Groningen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Maastricht :
A Study of RO5185426 in Patients With Metastatic Melanoma
Norway
Bergen :
A Study of RO5185426 in Patients With Metastatic Melanoma
Drammen : MSD (Norge) AS Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Oslo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Peru
Arequipa :
A Study of RO5185426 in Patients With Metastatic Melanoma
Lima :
A Study of RO5185426 in Patients With Metastatic Melanoma
Portugal
Porto :
A Study of RO5185426 in Patients With Metastatic Melanoma
Romania
Timisoara :
A Study of RO5185426 in Patients With Metastatic Melanoma
Serbia
Belgrade :
A Study of RO5185426 in Patients With Metastatic Melanoma
Slovenia
Ljubljana :
A Study of RO5185426 in Patients With Metastatic Melanoma
South Africa
Bloemfontein :
A Study of RO5185426 in Patients With Metastatic Melanoma
Cape Town :
A Study of RO5185426 in Patients With Metastatic Melanoma
Johannesburg :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pretoria :
A Study of RO5185426 in Patients With Metastatic Melanoma
Spain
Barcelona :
A Study of RO5185426 in Patients With Metastatic Melanoma
Barcelona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Cartagena (murcia) :
A Study of RO5185426 in Patients With Metastatic Melanoma
Cordoba :
A Study of RO5185426 in Patients With Metastatic Melanoma
Granada :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
La Coruna :
A Study of RO5185426 in Patients With Metastatic Melanoma
La Laguna (tenerife) :
A Study of RO5185426 in Patients With Metastatic Melanoma
Las Palmas de Gran Canaria :
A Study of RO5185426 in Patients With Metastatic Melanoma
Leon :
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid :
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Malaga :
A Study of RO5185426 in Patients With Metastatic Melanoma
Málaga :
A Study of RO5185426 in Patients With Metastatic Melanoma
Palma de Mallorca :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pamplona :
A Study of RO5185426 in Patients With Metastatic Melanoma
Pamplona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Salamanca :
A Study of RO5185426 in Patients With Metastatic Melanoma
Santander :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sevilla :
A Study of RO5185426 in Patients With Metastatic Melanoma
Valencia :
A Study of RO5185426 in Patients With Metastatic Melanoma
Vigo :
A Study of RO5185426 in Patients With Metastatic Melanoma
Zaragoza :
A Study of RO5185426 in Patients With Metastatic Melanoma
Sweden
Lund : Lunds Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Södersjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Karolinska Sjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Umeå : Norrlands Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Turkey
Adana :
A Study of RO5185426 in Patients With Metastatic Melanoma
Ankara :
A Study of RO5185426 in Patients With Metastatic Melanoma
Antalya :
A Study of RO5185426 in Patients With Metastatic Melanoma
Gaziantep :
A Study of RO5185426 in Patients With Metastatic Melanoma
Istanbul :
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Izmir :
A Study of RO5185426 in Patients With Metastatic Melanoma
United Kingdom
Birmingham : Queen Elizabeth Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Cambridge :
A Study of RO5185426 in Patients With Metastatic Melanoma
Cambridge : Addenbrooke's Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Glasgow :
A Study of RO5185426 in Patients With Metastatic Melanoma
Glasgow : The Beatson Institute
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
View More »
Leeds :
A Study of RO5185426 in Patients With Metastatic Melanoma
Leeds : St James' Institute of Oncology
Study of a DNA Immunotherapy to Treat Melanoma
Leeds : St James Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
London :
A Study of RO5185426 in Patients With Metastatic Melanoma
Manchester :
A Study of RO5185426 in Patients With Metastatic Melanoma
Manchester : Christie Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Newcastle Upon Tyne :
A Study of RO5185426 in Patients With Metastatic Melanoma
Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Northwood :
A Study of RO5185426 in Patients With Metastatic Melanoma
Northwood :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nottingham :
A Study of RO5185426 in Patients With Metastatic Melanoma
Nottingham : Department of Clinical Oncology, City Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Oxford :
A Study of RO5185426 in Patients With Metastatic Melanoma
Oxford : NIHR Biomedical Research Centre
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Southampton :
A Study of RO5185426 in Patients With Metastatic Melanoma
Southampton : Department of Medical Oncology, Southampton General Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Swansea :
A Study of RO5185426 in Patients With Metastatic Melanoma
